GOSSAMER BIO, INC. Operating Lease Cost
GOSSAMER BIO, INC. (GOSS) reported Operating Lease Cost of $371.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseCost · last filed 2026-08-13
- GOSSAMER BIO, INC. operating lease, cost for the quarter ending 2026-06-30 was $371.00K, a 3.34% increase year-over-year.
- GOSSAMER BIO, INC. operating lease, cost for the quarter ending 2026-03-31 was $358.00K, a 27.24% decline year-over-year.
- GOSSAMER BIO, INC. operating lease, cost for the quarter ending 2025-12-31 was $358.00K, a 68.51% decline year-over-year.
- GOSSAMER BIO, INC. operating lease, cost for the quarter ending 2025-09-30 was $358.00K, a 64.62% decline year-over-year.
- GOSSAMER BIO, INC. operating lease, cost for fiscal 2025 was $1.57M, a 57.72% decline from fiscal 2024.
- GOSSAMER BIO, INC. operating lease, cost for fiscal 2024 was $3.71M, a 19.01% increase from fiscal 2023.
- GOSSAMER BIO, INC. operating lease, cost for fiscal 2023 was $3.11M, a 0.55% increase from fiscal 2022.
- GOSSAMER BIO, INC. operating lease, cost for fiscal 2022 was $3.10M, a 23.13% decline from fiscal 2021.
| Period end | Operating Lease, Cost 3 month | Operating Lease, Cost 6 month | Operating Lease, Cost 9 month | Operating Lease, Cost 12 month |
|---|---|---|---|---|
| 2026-06-30 | $371.00K 10-Q · filed 2026-08-13 | $729.00K 10-Q · filed 2026-08-13 | $1.09M derived: sum of 3 quarters · filed 2026-08-13 | $1.45M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $358.00K 10-Q · filed 2026-05-15 | $716.00K derived: sum of 2 quarters · filed 2026-05-15 | $1.07M derived: sum of 3 quarters · filed 2026-05-15 | $1.43M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $358.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $716.00K derived: sum of 2 quarters · filed 2026-03-17 | $1.07M derived: sum of 3 quarters · filed 2026-08-13 | $1.57M 10-K · filed 2026-03-17 |
| 2025-09-30 | $358.00K 10-Q · filed 2025-11-05 | $717.00K derived: sum of 2 quarters · filed 2026-08-13 | $1.21M 10-Q · filed 2025-11-05 | $2.35M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $359.00K 10-Q · filed 2026-08-13 | $851.00K 10-Q · filed 2026-08-13 | $1.99M derived: sum of 3 quarters · filed 2026-08-13 | $3.00M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $492.00K 10-Q · filed 2026-05-15 | $1.63M derived: sum of 2 quarters · filed 2026-05-15 | $2.64M derived: sum of 3 quarters · filed 2026-05-15 | $3.42M derived: sum of 4 quarters · filed 2026-05-15 |
| 2024-12-31 | $1.14M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $2.15M derived: sum of 2 quarters · filed 2026-03-17 | $2.93M derived: sum of 3 quarters · filed 2026-03-17 | $3.71M 10-K · filed 2026-03-17 |
| 2024-09-30 | $1.01M 10-Q · filed 2025-11-05 | $1.79M derived: sum of 2 quarters · filed 2025-11-05 | $2.57M 10-Q · filed 2025-11-05 | $3.35M derived: sum of 4 quarters · filed 2026-03-17 |
| 2024-06-30 | $779.00K 10-Q · filed 2025-08-05 | $1.56M 10-Q · filed 2025-08-05 | $2.34M derived: sum of 3 quarters · filed 2026-03-17 | $3.11M derived: sum of 4 quarters · filed 2026-03-17 |
| 2024-03-31 | $778.00K 10-Q · filed 2025-05-15 | $1.56M derived: sum of 2 quarters · filed 2026-03-17 | $2.33M derived: sum of 3 quarters · filed 2026-03-17 | $3.11M derived: sum of 4 quarters · filed 2026-03-17 |
| 2023-12-31 | $779.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $1.56M derived: sum of 2 quarters · filed 2026-03-17 | $2.34M derived: sum of 3 quarters · filed 2026-03-17 | $3.11M 10-K · filed 2026-03-17 |
| 2023-09-30 | $778.00K 10-Q · filed 2024-11-07 | $1.56M derived: sum of 2 quarters · filed 2024-11-07 | $2.33M 10-Q · filed 2024-11-07 | $3.11M derived: sum of 4 quarters · filed 2025-03-13 |
| 2023-06-30 | $779.00K 10-Q · filed 2024-08-12 | $1.56M 10-Q · filed 2024-08-12 | $2.34M derived: sum of 3 quarters · filed 2025-03-13 | $3.11M derived: sum of 4 quarters · filed 2025-03-13 |
| 2023-03-31 | $778.00K 10-Q · filed 2024-05-07 | $1.56M derived: sum of 2 quarters · filed 2025-03-13 | $2.33M derived: sum of 3 quarters · filed 2025-03-13 | $3.11M derived: sum of 4 quarters · filed 2025-03-13 |
| 2022-12-31 | $779.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | $1.56M derived: sum of 2 quarters · filed 2025-03-13 | $2.34M derived: sum of 3 quarters · filed 2025-03-13 | $3.10M 10-K · filed 2025-03-13 |
| 2022-09-30 | $778.00K 10-Q · filed 2023-11-09 | $1.56M derived: sum of 2 quarters · filed 2023-11-09 | $2.32M 10-Q · filed 2023-11-09 | $3.26M derived: sum of 4 quarters · filed 2024-03-05 |
| 2022-06-30 | $779.00K 10-Q · filed 2023-08-08 | $1.54M 10-Q · filed 2023-08-08 | $2.48M derived: sum of 3 quarters · filed 2024-03-05 | $3.49M derived: sum of 4 quarters · filed 2024-03-05 |
| 2022-03-31 | $761.00K 10-Q · filed 2023-05-09 | $1.71M derived: sum of 2 quarters · filed 2024-03-05 | $2.71M derived: sum of 3 quarters · filed 2024-03-05 | $3.75M derived: sum of 4 quarters · filed 2024-03-05 |
| 2021-12-31 | $945.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-05 | $1.95M derived: sum of 2 quarters · filed 2024-03-05 | $2.99M derived: sum of 3 quarters · filed 2024-03-05 | $4.03M 10-K · filed 2024-03-05 |
| 2021-09-30 | $1.01M 10-Q · filed 2022-11-03 | $2.05M derived: sum of 2 quarters · filed 2022-11-03 | $3.08M 10-Q · filed 2022-11-03 | $4.12M derived: sum of 4 quarters · filed 2023-03-17 |
| 2021-06-30 | $1.04M 10-Q · filed 2022-08-09 | $2.08M 10-Q · filed 2022-08-09 | $3.11M derived: sum of 3 quarters · filed 2023-03-17 | $4.12M derived: sum of 4 quarters · filed 2023-03-17 |
| 2021-03-31 | $1.04M 10-Q · filed 2022-05-10 | $2.08M derived: sum of 2 quarters · filed 2023-03-17 | $3.08M derived: sum of 3 quarters · filed 2023-03-17 | $3.90M derived: sum of 4 quarters · filed 2023-03-17 |
| 2020-12-31 | $1.04M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-17 | $2.04M derived: sum of 2 quarters · filed 2023-03-17 | $2.86M derived: sum of 3 quarters · filed 2023-03-17 | $3.62M 10-K · filed 2023-03-17 |
| 2020-09-30 | $1.01M 10-Q · filed 2021-11-08 | $1.82M derived: sum of 2 quarters · filed 2021-11-08 | $2.58M 10-Q · filed 2021-11-08 | $3.33M derived: sum of 4 quarters · filed 2022-03-03 |
| 2020-06-30 | $817.00K 10-Q · filed 2021-08-09 | $1.57M 10-Q · filed 2021-08-09 | $2.32M derived: sum of 3 quarters · filed 2022-03-03 | $3.08M derived: sum of 4 quarters · filed 2022-03-03 |
| 2020-03-31 | $753.00K 10-Q · filed 2021-05-06 | $1.51M derived: sum of 2 quarters · filed 2022-03-03 | $2.26M derived: sum of 3 quarters · filed 2022-03-03 | $3.01M derived: sum of 4 quarters · filed 2022-03-03 |
| 2019-12-31 | $753.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-03 | $1.51M derived: sum of 2 quarters · filed 2022-03-03 | $2.26M derived: sum of 3 quarters · filed 2022-03-03 | $3.01M 10-K · filed 2022-03-03 |
| 2019-09-30 | $753.00K 10-Q · filed 2019-11-12 | $1.50M derived: sum of 2 quarters · filed 2019-11-12 | $2.26M 10-Q · filed 2019-11-12 | |
| 2019-06-30 | $752.00K 10-Q · filed 2019-08-08 | $1.50M 10-Q · filed 2019-08-08 | ||
| 2019-03-31 | $753.00K 10-Q · filed 2019-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 |